FER-TH-007: Phase II Study of Bevacizumab and Erlotinib in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NSCLC
- 04 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.
- 04 Sep 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 04 Sep 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.